Lundbeck is a medium-sized pharmaceutical company which specialises in diseases of old age and the central nervous system. While earnings growth is currently very strong, there is a huge risk to earnings from 2012, when a large number of the existing portfolio of drugs face patent expiry. The late-stage research pipeline, which last year had still looked very strong, has suffered a series of disappointments, making it less likely that the lost sales can be replaced; we therefore decided to sell the stock.
Lundbeck. The pharmaceutical sector is trading at a 15-year-low, as the majors are plagued with patent expiries and more aggressive pricing regimes. Lundbeck benefits from a reasonably young portfolio of drugs that play well to current demographic trends - focussing on Alzheimer's, depression and Parkinson's disease, which should have above average growth rates.
| Sedol |
Type |
Price |
Date |
| 7085259 |
Sell |
DKK 114.88 |
15/08/2008 |
| 7085259 |
Buy |
DKK 145.92 |
30/10/2007 | |